Given the persistence of residual disease in the axillary lymph nodes after neoadjuvant chemotherapy, the ongoing suspicion of metastatic progression, and the loss of hormone receptor expression in the recurrent tumor, capecitabine was introduced as an adjuvant therapy in June 2024, before confirming the exact nature of the splenic lesions. The gene discussed is NR4A1; the disease is neoplasm.